The following reactions have been reported with the use of lincomycin:

Gastrointestinal—Glossitis, stomatitis, nausea, vomiting, antibiotic-associated diarrhea and colitis, and pruritus ani. Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment (see WARNINGS).

Hematopoietic—Neutropenia, leukopenia, agranulocytosis and thrombocytopenic purpura have been reported. There have been rare reports of aplastic anemia and pancytopenia in which LINCOCIN could not be ruled out as the causative agent.

Hypersensitivity Reactions—Hypersensitivity reactions such as angioneurotic edema, serum sickness and anaphylaxis have been reported. Rare instances of erythema multiforme, some resembling Stevens-Johnson syndrome, have been associated with LINCOCIN. If an allergic reaction to LINCOCIN occurs, discontinue the drug. Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures, including oxygen, intravenous fluids, intravenous antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated.

Skin and Mucous Membranes—Skin rashes, urticaria and vaginitis and rare instances of exfoliative and vesiculobullous dermatitis have been reported.

Liver—Although no direct relationship of LINCOCIN to liver dysfunction has been established, jaundice and abnormal liver function tests (particularly elevations of serum transaminase) have been observed.

Renal—Although no direct relationship of lincomycin to renal damage has been established, renal dysfunction as evidenced by azotemia, oliguria, and/or proteinuria has been observed in rare instances.

Cardiovascular—After too rapid intravenous administration, rare instances of cardiopulmonary arrest and hypotension have been reported. (See DOSAGE AND ADMINISTRATION.)

Special Senses—Tinnitus and vertigo have been reported occasionally.

Local Reactions—Patients have demonstrated excellent local tolerance to intramuscularly administered LINCOCIN. Reports of pain following injection have been infrequent. Intravenous administration of LINCOCIN in 250 to 500 mL of 5% dextrose injection or 0.9% sodium chloride injection produced no local irritation or phlebitis.

Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used in caution in patients receiving such agents.

Antagonism between lincomycin and erythromycin in vitro has been demonstrated. Because of possible clinical significance, the two drugs should not be administered concurrently.

Bookmark this page: